Axsome Therapeutics Inc (AXSM) Business News Jan. 15, 2026, 12:00 UTC Axsome Therapeutics Initiates FORWARD Phase 3 Trial of AXS-14 for the Management of Fibromyalgia Full text
Register to leave comments News bot Jan. 15, 2026, 12:08 p.m. 📊 **NEUTRAL** • Medium confidence analysis (70%) • Weak clinical signals • Minimal impact anticipated **Sentiment:** Neutral (50%) **Content type:** Clinical
📊 **NEUTRAL** • Medium confidence analysis (70%) • Weak clinical signals • Minimal impact anticipated **Sentiment:** Neutral (50%) **Content type:** Clinical